Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELCNYSE:CORBFNASDAQ:SBCNASDAQ:TALK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$12.15+6.1%$11.16$7.58▼$19.77$433.57M0.37283,802 shs224,653 shsCORBFGlobal Cord Blood$1.50+27.1%$1.01$0.25▼$2.00$182.33M-0.66125,075 shs9,896 shsSBCSBC Medical Group$4.27-1.6%$4.05$2.62▼$12.50$449.67M1.3562,849 shs55,046 shsTALKTalkspace$2.87+4.0%$3.00$1.60▼$4.36$461.79M1.121.96 million shs1.54 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity-1.29%-8.11%+9.67%+8.94%-28.12%CORBFGlobal Cord Blood0.00%+12.38%+18.00%+47.50%-1.67%SBCSBC Medical Group+0.70%-2.25%-4.62%+14.81%+433,999,900.00%TALKTalkspace+2.99%-1.78%-2.13%-2.82%+29.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELCCelcuity1.1673 of 5 stars3.60.00.00.00.02.50.0CORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ASBCSBC Medical GroupN/AN/AN/AN/AN/AN/AN/AN/ATALKTalkspace3.9265 of 5 stars3.53.00.00.03.53.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.17Buy$30.80153.50% UpsideCORBFGlobal Cord Blood 0.00N/AN/AN/ASBCSBC Medical Group 0.00N/AN/AN/ATALKTalkspace 3.00Buy$4.5056.79% UpsideCurrent Analyst Ratings BreakdownLatest CORBF, TALK, SBC, and CELC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/6/2025TALKTalkspaceNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/11/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/3/2025TALKTalkspaceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.004/1/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$3.11 per shareN/ACORBFGlobal Cord Blood$196.12M0.93$1.07 per share1.40N/A∞SBCSBC Medical Group$205.42M2.15$0.60 per share7.16$1.90 per share2.25TALKTalkspace$187.59M2.56$0.01 per share232.30$0.69 per share4.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)CORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/ASBCSBC Medical Group$46.61MN/A0.000.76N/AN/A26.72%19.60%N/ATALKTalkspace$1.15M$0.02143.5715.11N/A1.51%2.54%2.15%8/5/2025 (Estimated)Latest CORBF, TALK, SBC, and CELC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SBCSBC Medical Group$0.11$0.21+$0.10$0.21$51.52 million$47.33 million5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A3/31/2025Q4 2024CELCCelcuity-$0.72-$0.85-$0.13-$0.85N/AN/A3/28/2025Q4 2024SBCSBC Medical Group$0.17$0.18+$0.01$0.06$56.34 million$57.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/ASBCSBC Medical GroupN/AN/AN/AN/AN/ATALKTalkspaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity1.146.616.61CORBFGlobal Cord BloodN/AN/AN/ASBCSBC Medical Group0.034.444.40TALKTalkspaceN/A6.496.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%CORBFGlobal Cord BloodN/ASBCSBC Medical Group60.82%TALKTalkspace57.37%Insider OwnershipCompanyInsider OwnershipCELCCelcuity15.78%CORBFGlobal Cord Blood0.50%SBCSBC Medical Group89.47%TALKTalkspace23.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4037.87 million31.89 millionOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableSBCSBC Medical GroupN/A103.61 million10.91 millionN/ATALKTalkspace500167.32 million128.00 millionOptionableCORBF, TALK, SBC, and CELC HeadlinesRecent News About These CompaniesTalkspace, Inc. (NASDAQ:TALK) Given Consensus Recommendation of "Buy" by BrokeragesJune 22 at 4:05 AM | marketbeat.comTalkspace (NASDAQ:TALK) Shares Up 5.2% - Still a Buy?June 11, 2025 | marketbeat.comTalkspace (NASDAQ:TALK) Shares Gap Down - Should You Sell?June 10, 2025 | marketbeat.comSquarepoint Ops LLC Lowers Stake in Talkspace, Inc. (NASDAQ:TALK)June 10, 2025 | marketbeat.comInsider Selling: Talkspace, Inc. (NASDAQ:TALK) CMO Sells 39,000 Shares of StockJune 7, 2025 | insidertrades.comKatelyn Watson Sells 39,000 Shares of Talkspace, Inc. (NASDAQ:TALK) StockJune 6, 2025 | marketbeat.comTalkspace to Participate in Upcoming Investor ConferencesJune 6, 2025 | globenewswire.comTalkspace And 2 Other Compelling Penny Stocks To ConsiderJune 5, 2025 | finance.yahoo.comTalkspace (NASDAQ:TALK) Stock Price Down 4.4% - What's Next?June 4, 2025 | marketbeat.comNuveen Asset Management LLC Boosts Holdings in Talkspace, Inc. (NASDAQ:TALK)June 4, 2025 | marketbeat.comTwo Sigma Advisers LP Decreases Holdings in Talkspace, Inc. (NASDAQ:TALK)June 3, 2025 | marketbeat.comTwo Sigma Investments LP Buys 82,921 Shares of Talkspace, Inc. (NASDAQ:TALK)June 2, 2025 | marketbeat.comMillennium Management LLC Boosts Holdings in Talkspace, Inc. (NASDAQ:TALK)May 31, 2025 | marketbeat.comTalkspace (NASDAQ:TALK) Shares Gap Up - Still a Buy?May 30, 2025 | marketbeat.comShares of Talkspace Climb After Amazon Pharmacy PartnershipMay 29, 2025 | marketwatch.comTalkspace, Inc. (NASDAQ:TALK) Receives Consensus Recommendation of "Buy" from AnalystsMay 29, 2025 | marketbeat.comMan Group plc Buys New Position in Talkspace, Inc. (NASDAQ:TALK)May 28, 2025 | marketbeat.comNorthern Trust Corp Acquires 109,432 Shares of Talkspace, Inc. (NASDAQ:TALK)May 25, 2025 | marketbeat.comNew York banning smart phones in schoolMay 18, 2025 | msn.comDigital health companies faced a rocky start to 2025May 9, 2025 | modernhealthcare.comMental Health and Substance Misuse Treatment Is Increasingly a Video Chat or Phone Call AwayMay 9, 2025 | californiahealthline.orgNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverCORBF, TALK, SBC, and CELC Company DescriptionsCelcuity NASDAQ:CELC$12.15 +0.70 (+6.11%) Closing price 04:00 PM EasternExtended Trading$12.10 -0.05 (-0.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Global Cord Blood NYSE:CORBF$1.50 +0.32 (+27.12%) As of 01:33 PM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.SBC Medical Group NASDAQ:SBC$4.27 -0.07 (-1.61%) Closing price 04:00 PM EasternExtended Trading$4.27 0.00 (0.00%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.Talkspace NASDAQ:TALK$2.87 +0.11 (+3.99%) Closing price 04:00 PM EasternExtended Trading$2.86 -0.01 (-0.49%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talkspace, Inc. operates as a virtual behavioral healthcare company in the United States. The company offers psychotherapy and psychiatry services through its platform to individuals, enterprises, and health plans and employee assistance programs. It provides text, audio, and video-based psychotherapy from licensed therapists. The company offers Talkspace Employee Assistance Program (EAP) and Talkspace Behavioral Health plan (BH) that provides online therapy to members through BH and EAP offerings; and Talkspace for Business for members to access its platform services on a benefit plan paid by the enterprise. It serves its platform through third-party platforms or marketplace, such as Apple App Store and Google Play App Store. Talkspace, Inc. was founded in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
